Epinephrine intranasal spray - INSYS Therapeutics

Drug Profile

Epinephrine intranasal spray - INSYS Therapeutics

Alternative Names: Epinephrine nasal spray

Latest Information Update: 21 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Class Antiarrhythmics; Antihaemorrhagics; Antihypotensives; Bronchodilators; Catecholamines; Ethanolamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anaphylaxis

Most Recent Events

  • 18 Jun 2018 INSYS Therapeutics announces intention to submit NDA to the US FDA for Anaphylaxis in 2019
  • 14 Jun 2018 Preliminary pharmacokinetics data from a phase I trial in Anaphylaxis released by INSYS Therapeutics
  • 08 Dec 2017 Phase-I clinical trials in Anaphylaxis (In volunteers) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top